Aegerion Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 57   

Articles published

AEGR 45.31 +1.39 (3.16%)
price chart
Aegerion starts Japanese Phase III trial of cholesterol drug
Aegerion Pharmaceuticals (AEGR) has started a Phase 3 Trial in Japan to evaluate its Lomitapide treatment for cutting low-density lipoprotein ("bad") cholesterol (LDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).
Aegerion Shares Up on Study Initiation  Zacks.com
Related articles »  
Ned Davis Research Upgrades Aegerion Pharmaceuticals to Neutral (AEGR)
Aegerion Pharmaceuticals, Inc. logo Aegerion Pharmaceuticals (NASDAQ:AEGR) was upgraded by equities researchers at Ned Davis Research from a �sell� rating to a �neutral� rating in a research report issued on Monday, AnalystRatings.
UPDATE: Aegerion Pharma Commences Phase 3 Clinical Trial in Japan, Will ...
Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with debilitating rare diseases, today announced that patient enrollment has been initiated in ...
Aegerion Pharmaceuticals Initiates Phase 3 Clinical Trial in Japan to ...  NASDAQ
Related articles »  
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
CAMBRIDGE, Mass., April 7, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases ...
Related articles »  
Biotech Most Volatile: Neuralstem (NYSEMKT:CUR), Aegerion Pharmaceuticals ...
Neuralstem, Inc. (NYSEMKT:CUR) announced that a study published in the peer-reviewed journal, PLOS ONE, showed that ischemic-stroke rats transplanted with Neuralstem Inc. (NYSEMKT:CUR)'s NSI-566 stem cells in the brain experienced functional ...
Hot Stocks: Generex Biotechnology Corporation (OTCMKTS:GNBT), Neuralstem ...  Techsonian (press release)
Related articles »  
Aegerion Pharmaceuticals Insider Craig Fraser Sells 2250 Shares (AEGR)
Aegerion Pharmaceuticals, Inc (NASDAQ:AEGR) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders.
Related articles »  
Aegerion Pharmaceuticals Rating Increased to Neutral at Ned Davis Research ...
Aegerion Pharmaceuticals, Inc (NASDAQ:AEGR) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders.
Related articles »  
Stocks Buzz - Depomed Inc (NASDAQ:DEPO), BioScrip Inc (NASDAQ:BIOS ...
Aegerion Pharmaceuticals, Inc (NASDAQ:AEGR) recently declared that patient enrollment has been initiated in Japan in a clinical trial of lomitapide as an adjunct treatment to reduce low-density lipoprotein cholesterol (LDL-C) in Japanese patients with ...
Related articles »  
Stocks Roundup-Trina Solar Limited (ADR) (NYSE:TSL), Aegerion ...
Aegerion Pharmaceuticals, Inc. (AEGR) a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States.
Related articles »  
News Review - Senomyx Inc (NASDAQ:SNMX), Aegerion Pharmaceuticals, Inc ...
Senomyx Inc. (NASDAQ:SNMX) reported gain +5.68% and closed at $10.79 with the total traded volume of 1.67 million shares. Its market capitalization is $449.30 million.
Related articles »